Literature DB >> 16493493

Therapeutic neovascularization by transplantation of mobilized peripheral blood mononuclear cells for limb ischemia. A comparison between CD34+ and CD34- mononuclear cells.

Shu Li1, Bin Zhou, Zhong Chao Han.   

Abstract

Autolougous transplantation of granulocyte colony-stimulating factor (G-CSF)-mobilized human peripheral blood mononuclear cells (PBMNCs) improves limb ischemia in patients with arteriosclerosis obliterans of lower extremities and with diabetic foot. However, the mechanism of action of PBMNCs remains elusive. Here, we studied comparatively the effects of the G-CSF-mobilized PBMNCs and CD34-depleted G-CSF-mobilized PBMNCs in an ischemia model of athymic nude mice. Fluorescence- labeled human PBMNCs [1 x 10(6)] were intramuscularly injected into the unilateral ischemic hindlimbs of mice. Laser Doppler imaging analysis revealed a significantly augmented blood perfusion at day 7, 14 and 28 after operation. The capillary density was also markedly increased and the rate of limb loss was significantly reduced in cell-transplanted groups when compared with those in PBS group. In comparison with G-CSF-mobilized PBMNCs, the therapeutic efficiency of G-CSF-mobilized PBMNCs deprived of CD34+ cells was impaired. Transplanted cells were found to accumulate around arterioles and scatter in capillary networks. Incorporation of transplanted cells into new capillaries was observed in the G-CSF-mobilized PBMNCs group, but was not detected in the group deprived of CD34+ cells. There was an elevated expression of VEGF in ischemic tissue. Colocalization of VEGF and transplanted mononuclear cells within adductor tissue was demonstrated. These findings indicate that G-CSF-mobilized PBMNCs promote vascular growth not only by incorporating into vessel walls but also by supplying angiogenic factors. The depletion of CD34+ cells attenuated the therapeutic efficiency of G-CSF-mobilized PBMNCs in response to ischemia-induced neovascularization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16493493     DOI: 10.1160/TH05-06-0442

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  13 in total

Review 1.  CD34-positive stem cells: in the treatment of heart and vascular disease in human beings.

Authors:  Alexander R Mackie; Douglas W Losordo
Journal:  Tex Heart Inst J       Date:  2011

2.  PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMI.

Authors:  Arshed A Quyyumi; Alejandro Vasquez; Dean J Kereiakes; Marc Klapholz; Gary L Schaer; Ahmed Abdel-Latif; Stephen Frohwein; Timothy D Henry; Richard A Schatz; Nabil Dib; Catalin Toma; Charles J Davidson; Gregory W Barsness; David M Shavelle; Martin Cohen; Joseph Poole; Thomas Moss; Pamela Hyde; Anna Maria Kanakaraj; Vitaly Druker; Amy Chung; Candice Junge; Robert A Preti; Robin L Smith; David J Mazzo; Andrew Pecora; Douglas W Losordo
Journal:  Circ Res       Date:  2016-11-07       Impact factor: 17.367

3.  Human CD34+ stem cells promote healing of diabetic foot ulcers in rats.

Authors:  Mohamed A Elsharawy; Magda Naim; Sahar Greish
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-12-01

Review 4.  Imaging stem cell therapy for the treatment of peripheral arterial disease.

Authors:  Julia D Ransohoff; Joseph C Wu
Journal:  Curr Vasc Pharmacol       Date:  2012-05       Impact factor: 2.719

Review 5.  Cell-based interventions for therapeutic angiogenesis: review of potential cell sources.

Authors:  Robert A Brenes; Mackenzie Bear; Caroline Jadlowiec; Matthew Goodwin; Peter Hashim; Clinton D Protack; Kenneth R Ziegler; Xin Li; Lynn S Model; Wei Lv; Michael J Collins; Alan Dardik
Journal:  Vascular       Date:  2012-10-19       Impact factor: 1.285

6.  Prognostic significance of circulating and endothelial progenitor cell markers in type 2 diabetic foot.

Authors:  Maria Sambataro; Elena Seganfreddo; Fabio Canal; Anna Furlan; Laura Del Pup; Monia Niero; Agostino Paccagnella; Filippo Gherlinzoni; Angelo Paolo Dei Tos
Journal:  Int J Vasc Med       Date:  2014-02-03

7.  Genetic targeting of sprouting angiogenesis using Apln-CreER.

Authors:  Qiaozhen Liu; Tianyuan Hu; Lingjuan He; Xiuzhen Huang; Xueying Tian; Hui Zhang; Liang He; Wenjuan Pu; Libo Zhang; Heng Sun; Jing Fang; Ying Yu; Shengzhong Duan; Chaobo Hu; Lijian Hui; Haibin Zhang; Thomas Quertermous; Qingbo Xu; Kristy Red-Horse; Joshua D Wythe; Bin Zhou
Journal:  Nat Commun       Date:  2015-01-19       Impact factor: 14.919

Review 8.  Angiogenic CD34 Stem Cell Therapy in Coronary Microvascular Repair-A Systematic Review.

Authors:  Balaj Rai; Janki Shukla; Timothy D Henry; Odayme Quesada
Journal:  Cells       Date:  2021-05-08       Impact factor: 7.666

Review 9.  Are We Ready for Cell Therapy to Treat Stroke?

Authors:  Fernando José Rascón-Ramírez; Noelia Esteban-García; Juan Antonio Barcia; Albert Trondin; Cristina Nombela; Leyre Sánchez-Sánchez-Rojas
Journal:  Front Cell Dev Biol       Date:  2021-06-23

10.  Tetanus toxoid-pulsed monocyte vaccination for augmentation of collateral vessel growth.

Authors:  Joerg Herold; Alexander Francke; Soenke Weinert; Alexander Schmeisser; Katrin Hebel; Burkhart Schraven; Friedich-Wilhelm Roehl; Ruth H Strasser; Ruediger C Braun-Dullaeus
Journal:  J Am Heart Assoc       Date:  2014-04-14       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.